Analyst Price Targets — EYPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:17 pm | — | Mizuho Securities | $36.00 | $14.36 | TheFly | EyePoint price target raised to $36 from $33 at Mizuho |
| February 5, 2026 1:54 pm | Lisa Walter | RBC Capital | $39.00 | $13.22 | StreetInsider | RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity' |
| October 29, 2025 12:50 pm | Graig Suvannavejh | Mizuho Securities | $33.00 | $12.25 | TheFly | EyePoint price target raised to $33 from $28 at Mizuho |
| October 20, 2025 10:55 am | Graig Suvannavejh | Mizuho Securities | $28.00 | $11.63 | StreetInsider | Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT) |
| November 11, 2024 12:23 pm | Yi Chen | H.C. Wainwright | $22.00 | $11.59 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright |
| May 13, 2024 7:17 am | Yi Chen | H.C. Wainwright | $30.00 | $12.17 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at H.C. Wainwright |
| May 7, 2024 6:34 am | Graig Suvannavejh | Mizuho Securities | $30.00 | $11.20 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at Mizuho |
| August 4, 2022 6:36 am | — | H.C. Wainwright | $25.00 | $10.22 | Benzinga | HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $25 |
Latest News for EYPT
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent…
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: TD Cowen 46 th Annual Health Care Conference Forum: Fireside Chat Date: March 3, 2026Time: 2:30…
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis ® and Xiidra ® –
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EYPT.
U.S. House Trading
No House trades found for EYPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.